RhTPO ( DrugBank: rhTPO )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
60再生不良性貧血3
63特発性血小板減少性紫斑病12

60. 再生不良性貧血


臨床試験数 : 245 薬物数 : 318 - (DrugBank : 86) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 166
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR2200056625
2022-03-012022-02-09Clinical study of aplastic anemia combined with recombinant human thrombopoietin and immunosuppressants in the treatment of severe aplastic anemia aplastic anemiaClinical study of aplastic anemia combined with recombinant human thrombopoietin and immunosuppressants in the treatment of severe aplastic anemia aplastic anemia Severe Aplastic Anemia1:IST+rhTPO+Etrapropa;Henan Cancer HospitalNULLPending470Both1:20;N/AChina
2ChiCTR1800019669
2019-01-012018-11-21A randomized, open-label, single-center controlled trial for the efficacy and safety of recombinant human thrombopoietin injection in the treatment of severe Aplastic Anemia with thrombocytopeniaA randomized, open-label, single-center controlled trial for the efficacy and safety of recombinant human thrombopoietin injection in the treatment of severe Aplastic Anemia with thrombocytopenia Aplastic anemia,ThrombocytopeniaGroup 1:Add rhTPO, 300U/kg qd after ATG treatment for 8 weeks;Group 2:Add rhTPO, 300U/kg qod after ATG treatment for 8 weeks;Institute of Hematology, People's Hospital, Peking UniversityNULLPendingBothGroup 1:30;Group 2:30;China
3NCT02857530
(ClinicalTrials.gov)
August 201626/7/2016Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic AnemiaEfficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic AnemiaAnemia, AplasticDrug: rhTPO;Drug: placeboTianjin Medical University General HospitalNULLNot yet recruiting6 Years60 YearsBoth250Phase 2China

63. 特発性血小板減少性紫斑病


臨床試験数 : 391 薬物数 : 235 - (DrugBank : 50) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 139
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05583838
(ClinicalTrials.gov)
November 22, 202212/10/2022A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP PtsComparing the Efficacy and Safety of Optimized rhTPO Treatment Versus Eltrombopag Treatment in Previously Treated Primary Immune Thrombocytopenia Patients: A Multicenter Randomized Open-label TrialPreviously Treated Primary Immune ThrombocytopeniaDrug: rhTPO;Drug: EltrombopagInstitute of Hematology & Blood Diseases HospitalThe Second Hospital of Hebei Medical University;Xijing Hospital;The Affiliated Hospital of Inner Mongolia Medical University;The Second Affiliated Hospital of Kunming Medical University;Second Affiliated Hospital of Guangzhou Medical University;Shaanxi Provincial People's Hospital;Henan Cancer Hospital;North China University of Science and Technology Affiliated Hospital;Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;The Second Affiliated Hospital of Dalian Medical University;Second Hospital of Shanxi Medical University;The Second Affiliated Hospital of Harbin Medical University;Daqing Oil Field Hospital;Cangzhou Central Hospital;Yuncheng Central Hospital;Shenyang Sunshine Pharmaceutical Co., LTD.Recruiting18 Years85 YearsAll175Phase 4China
2ChiCTR2000039630
2021-01-012020-11-03Phase II clinical trial of the superiority of montelukastine in combination with TPO-MPL agonists for the treament of primary immune thrombocytopeniaPhase II clinical trial of the superiority of montelukastine in combination with TPO-MPL agonists for the treament of primary immune thrombocytopenia Primary immune thrombocytopeniaexperimental group:Montelukast sodium 10mg/day; rhTPO 15000 units;control group:rhTPO 15000 units;Department of Hematology, Second Medical Center, Chinese PLA General HospitalNULLRecruiting1480Bothexperimental group:51;control group:51;Phase 2China
3ChiCTR1900027735
2020-01-012019-11-24Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP)Clinical study for high-dose dexamethasone combined with versus without human recombinant thrombopoietin (rhTPO) in the treatment of newly diagnosed primary immune thrombocytopenia (ITP) Adult newly diagnosed immune thrombocytopeniaStudy group:Dexamethasone 40mg/d×4d, recombinant human thrombopoietin (rhTPO) 300U/Kg subcutaneous injection, once/d×14d, if PLT>100×109/L or PLT increase =50×109/L during treatment period RhTPO drug was discontinued; rhTPO and dexamethasone were replaced with prednisone 0.5mg~1mg/kg once a day, 0.2mg/kg per week, and the drug was stopped wit;Control group:Dexamethasone 40mg/d×4d, if the PLT>100×10^9/L or PLT increase =50×10^9/L during the treatment period, dexamethasone was replaced with prednisone 0.5mg~ 1mg/kg orally every day, reduce 0.2mg/kg per week, and quickly reduce the dose within 6~8 weeks.;Department of Hematology, Anhui Provincial HospitalNULLPending1880BothStudy group:30;Control group:30;Phase 4China
4NCT03771378
(ClinicalTrials.gov)
January 16, 20197/12/2018Efficacy and Safety of rhTPO and Eltrombopag in Patients With Primary Immune Thrombocytopenia (ITP)Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled TrialPrimary Immune ThrombocytopeniaDrug: rhTPO;Drug: eltrombopagWuhan Union Hospital, ChinaThe First Affiliated Hospital of Nanchang University;The Third Xiangya Hospital of Central South University;The First People's Hospital of Yuhang District;Xiangyang Central HospitalRecruiting18 Years75 YearsAll96Phase 4China
5NCT04089267
(ClinicalTrials.gov)
December 201610/9/2019Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)Multicenter, Randomized, Open, Parallel Controlled Trials Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)ITPDrug: TPOShenyang Sunshine Pharmaceutical Co., LTD.NULLCompleted18 YearsN/AAll288Phase 4China
6ChiCTR-INR-16009363
2016-10-132016-10-10'Yu Xue Qi Huo' theory based integrated Traditional Chinese and Western Medicine in the diagnosis and treatment of stratified relapsed and refractory primary immune thrombocytopenia'Yu Xue Qi Huo' theory based integrated Traditional Chinese and Western Medicine in the diagnosis and treatment of stratified relapsed and refractory primary immune thrombocytopenia Immune ThrombocytopeniaStudy Group A:Yangyin Traditional Chinese Medicine: brew the TCM granules in warm water, 1 pack bid p.o. 1 hour after meal for 6 months continuously;Study Group A:Cyclosporin A capsules: 5mg/kg/d p.o., adjusted according to the serum CsA concentration;Control group B:Traditional Chinese Medicine for control group;Control group B:Cyclosporin A capsules: 5mg/kg/d p.o., adjusted according to the serum CsA concentration ;Study Group C:Yangyin Traditional Chinese Medicine: brew the TCM granules in warm water, 1 pack bid p.o. 1 hour after meal for 6 months continuously ;Study Group C:rhTPO: 1ug/kg/d qd for 14 days continuously, ih, until platelet count reaches 100×10^9/L;Control Group D:Traditional Chinese Medicine for control group;Control Group D:rhTPO: 1ug/kg/d qd for 14 days continuously, ih, until platelet count reaches 100×10^9/L ;Ruijin Hospital affiliated to Shanghai Jiaotong University School of MedicineNULLRecruiting1875BothStudy Group A:55;Study Group A:55;Control group B:55;Control group B:55;Study Group C:45;Study Group C:45;Control Group D:45;Control Group D:45;China
7NCT02139501
(ClinicalTrials.gov)
May 201413/5/2014An Investigation of rhTPO With Different Frequencies in the Management of ITPA Randomized Study to Evaluate the Efficacy and Safety of Different Doses and Frequencies of Recombinant Human Thrombopoietin (rhTPO) in the Management of Primary Immune Thrombocytopenia (ITP)Immune ThrombocytopeniaDrug: Recombinant Human Thrombopoietin (rhTPO)Shandong UniversityThe First Affiliated Hospital of Dalian Medical University;Shandong Provincial HospitalCompleted18 Years60 YearsBoth48Phase 3China
8NCT01734044
(ClinicalTrials.gov)
July 201221/11/2012rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITPA Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: recombinant human thrombopoietin (rhTPO); dexamethasone;Drug: DexamethasoneShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;China Medical University, China;Zhejiang Provincial Hospital of TCMCompleted18 Years75 YearsBoth158Phase 3China
9NCT01734057
(ClinicalTrials.gov)
July 201221/11/2012Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: recombinant human thrombopoietin (rhTPO); rituximab;Drug: DexamethasoneShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;China Medical University, China;Zhejiang Provincial Hospital of TCMWithdrawn18 Years75 YearsBoth0Phase 3China
10NCT01525836
(ClinicalTrials.gov)
May 201131/1/2012rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITPRecombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP.Purpura;Idiopathic Thrombocytopenic PurpuraDrug: rituximab; recombinant human thrombopoietin (rhTPO);Drug: RituximabShandong UniversityThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences;The First Affiliated Hospital of Anhui Medical University;The First Affiliated Hospital of Dalian Medical University;Shandong Provincial Hospital;Shenzhen Second People's Hospital;First Hospital of China Medical UniversityCompleted18 Years72 YearsBoth123Phase 3China
11NCT01805648
(ClinicalTrials.gov)
February 201122/2/2013Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITPA Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune ThrombocytopeniaThrombocytopenia;Immune Thrombocytopenia;Idiopathic Thrombocytopenic PurpuraDrug: rhTPOPeking Union Medical CollegeShenyang Sunshine Pharmaceutical Co., LTD.Recruiting14 Years70 YearsBoth120Phase 3China
12NCT01506414
(ClinicalTrials.gov)
June 200916/11/2011Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)A Multicentre Investigation of Recombinant Human Thrombopoietin (Rh-TPO) Combine With Low-dose Rituximab in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)Purpura;Idiopathic Thrombocytopenic PurpuraDrug: rhTPO in combination with RituximabMing HouPeking Union Medical College Hospital;Chinese Academy of Medical Sciences;First Affiliated Hospital, Sun Yat-Sen University;West China Hospital;Shandong Provincial Hospital;Wuhan Union Hospital, China;Zhejiang UniversityCompleted16 Years75 YearsBoth91Phase 3China